Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cambridge Health Alliance
After being informed of the study and potential risks and benefits, patients meeting eligibility requirements will be randomized to receive oral N-acetylcysteine (NAC) as follows:
Inpatients:
* N-acetylcystine (NAC) 25 mg/kg PO (rounded up to the nearest 600 mg) q4hrs until discharge
* N-acetylcysteine (NAC) 1200 mg PO BID x 1 week post-discharge
Outpatients:
\- N-acetylcysteine (NAC) 2400 mg PO x 1 then 1200 mg PO BID x 2 weeks
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
known or suspect COVID-19 disease AND one or more of the following influenza-like symptoms, including: diarrhea vomiting fever (subjective or measured) chills myalgias fatigue sore throat headache cough nasal/sinus congestion or rhinorrhea shortness of breath chest pain
You may not be if
Minors, pregnant women and people unable to provide informed consent are excluded from this study
Clareo Health | Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
